English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives: Asthma is one of the most common chronic diseases worldwide and can often be controlled by treatments. However, in 5-10% of patients have severe asthma. Anti-IgE (Omalizumab) is indicated for asthma patients who have an allergic-sensitivity with a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids. There are papers that patients with severe asthma are non-adherent to treatment or that their compliance to preventer inhaler treatments after omalizumab treatment is impaired. We aimed to evaluate the adherence with preventer inhaler therapy in severe asthmatic patients receiving omalizumab.

Evaluation of Non-Adherence with Preventer Inhaler Therapy in Severe Asthmatics Patients Receiving Omalizumab